Analysts predict that Express Scripts Holding Co (NASDAQ:ESRX) will announce $2.42 earnings per share (EPS) for the current quarter, Zacks reports. Nine analysts have made estimates for Express Scripts’ earnings, with estimates ranging from $2.40 to $2.43. Express Scripts posted earnings per share of $1.90 in the same quarter last year, which would indicate a positive year-over-year growth rate of 27.4%. The firm is expected to announce its next earnings report on Tuesday, October 23rd.
On average, analysts expect that Express Scripts will report full year earnings of $9.07 per share for the current fiscal year, with EPS estimates ranging from $9.00 to $9.10. For the next financial year, analysts forecast that the business will report earnings of $9.46 per share, with EPS estimates ranging from $9.04 to $10.15. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Express Scripts.
Express Scripts (NASDAQ:ESRX) last released its quarterly earnings data on Wednesday, August 1st. The company reported $2.22 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.20 by $0.02. The business had revenue of $25.64 billion for the quarter, compared to the consensus estimate of $25.43 billion. Express Scripts had a net margin of 4.65% and a return on equity of 25.49%. The company’s revenue was up 1.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.73 earnings per share.
Shares of ESRX opened at $96.03 on Wednesday. Express Scripts has a twelve month low of $55.80 and a twelve month high of $96.45. The stock has a market cap of $53.41 billion, a PE ratio of 13.53, a P/E/G ratio of 1.20 and a beta of 1.01. The company has a current ratio of 0.71, a quick ratio of 0.59 and a debt-to-equity ratio of 0.69.
In related news, insider Christine Houston sold 12,898 shares of the company’s stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $85.00, for a total value of $1,096,330.00. Following the transaction, the insider now directly owns 110,908 shares in the company, valued at $9,427,180. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.79% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in Express Scripts by 1.5% in the second quarter. BlackRock Inc. now owns 35,424,185 shares of the company’s stock worth $2,735,103,000 after buying an additional 538,578 shares in the last quarter. Northern Trust Corp boosted its stake in Express Scripts by 0.4% in the second quarter. Northern Trust Corp now owns 10,205,190 shares of the company’s stock worth $787,943,000 after buying an additional 40,656 shares in the last quarter. Abrams Capital Management L.P. purchased a new stake in Express Scripts in the second quarter worth approximately $204,846,000. American Century Companies Inc. boosted its stake in Express Scripts by 18.9% in the second quarter. American Century Companies Inc. now owns 2,492,801 shares of the company’s stock worth $192,469,000 after buying an additional 395,723 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Express Scripts by 6.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,024,126 shares of the company’s stock worth $156,283,000 after buying an additional 120,214 shares in the last quarter. Institutional investors own 84.73% of the company’s stock.
Express Scripts Company Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Read More: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.